

**CANCER REPORTING IN CALIFORNIA:**  
**ABSTRACTING AND CODING PROCEDURES**  
**California Cancer Reporting System Standards, Volume I**

*Changes and Clarifications –16<sup>th</sup> Edition*  
*April 15, 2016*

**Quick Look- Updates to Volume I**

**New Data Items**

<b><u>VOL I Section #</u></b>	<b><u>Data Item</u></b>	<b><u>Requirement</u></b>
V.4.1.1	Tumor Size Clinical	Required
V.4.1.2	Tumor Size Pathologic	Required
V.4.1.3	Tumor Size Summary	Required
V.4.2	Mets at Dx-Bone	Required
V.4.2	Mets at Dx-Brain	Required
V.4.2	Mets at Dx-Distant LN	Required
V.4.2	Mets at Dx-Liver	Required
V.4.2	Mets at Dx-Lung	Required
V.4.2	Mets at DX-Other	Required

**Other Sections Added/Revised Required**

<b><u>VOL I Section #</u></b>	<b><u>Data Item</u></b>	<b><u>Requirement</u></b>
V.6	AJCC Staging – TNM Indicators/Prefixes	Required
V.6.2.1	Clinical T	Required
V.6.2.2	Clinical N	Required
V.6.2.3	Clinical M	Required
V.6.2.4	Clinical Stage Group	Required
V.6.2.5	Clinical Stage Descriptor	Required
V.6.3.1	Pathologic T	Required
V.6.3.2	Pathologic N	Required
V.6.3.3	Pathologic M	Required
V.6.3.4	Pathologic Stage Group	Required
V.6.3.5	Pathologic Stage Descriptor	Required
VI.2.3	Regional Nodes Examined	Required
VI.2.3.1	Regional Nodes Positive	Required
VI.2.7	RX Summ – Surgical Margins	Required

**Items No Longer Required**

<b><u>VOL I Section #</u></b>	<b><u>Data Item</u></b>	<b><u>Requirement</u></b>
II.2.7	Borderline Ovarian Tumors	<i>Not required for cases diagnosed January 1, 2016 forward.</i>
V.4	CS Tumor Size	<i>Not required for cases diagnosed January 1, 2016 forward. The data items Tumor Size Clinical, Tumor Size Pathologic, and Tumor Size Summary replace this data item.</i>
V.4	CS Extension	<i>Not required for cases diagnosed January 1, 2016 forward.</i>
V.4	CS Tumor Size/Ext Eval	<i>Not required for cases diagnosed January 1, 2016 forward.</i>
V.4	CS Lymph Nodes	<i>Not required for cases diagnosed January 1, 2016 forward.</i>
V.4	CS Lymph Nodes Eval	<i>Not required for cases diagnosed January 1, 2016 forward.</i>
V.4.4.1	CS Mets at DX – Bone Brain, Liver, and Lung	<i>Not required for cases diagnosed January 1, 2016 forward. The data items Mets at Diagnosis – Bone, Brain, Distant LNS, Liver, Lung and Other replace this item.</i>
V.4	CS Mets Eval	<i>Not required for cases diagnosed January 1, 2016 forward.</i>

## **GENERAL CHANGES**

### **All Pages:**

- ✓ Per Standard Setters terminology change, most references to “Hospital” throughout Volume I have been updated to “Reporting Facility” or “Facility.”

### **Select Pages:**

- ✓ Removed “for Hospitals” from the title of Volume I and from the header of all pages.
- ✓ Updated Volume I page number links to page name links.

## **SECTION CHANGES**

### **I.1.3 State Cancer Reporting Requirements**

- ✓ Removed “borderline ovarian cancer” from the first bullet in the guidelines section.

### **I.1.6.1 Definition of Cancer**

- ✓ Removed second bullet regarding requirement of borderline ovarian tumors.

### **I.1.6.5 Coding Resources**

- ✓ Reordered the Abstracting and Coding Manual list to display the current coding manuals first.
- ✓ Updated release dates of the Abstracting and Coding Manuals.

### **II.1 CCR Reportability Guide**

- ✓ Updated Borderline Ovarian section:
  - Non-reportable = 2016+
  - Reportable = behavior /3 pre-2001 or behavior /1 for 2001- 2015
- ✓ Minor formatting changes.

### **II.2 Determining Reportability**

- ✓ Removed fourth bullet regarding requirement of borderline ovarian tumors.

### **II.2.1 Criteria for Reportability of Benign/Borderline brain and CNS tumors**

- ✓ This page was **deleted** as it was a duplication of information in section II.2.6 Benign/Borderline Brain and CNS Tumors.
- ✓ As a result of the deleted page, the following pages have been renumbered to:
  - **II.2.1 (from II.2.2) Identifying the Primary Neoplasm and Single or Multiple Tumors**
  - **II.2.2 (from II.2.3) Skin Reportability**
  - **II.2.3 (from II.2.4) Ambiguous Diagnostic Reportable Terms**
  - **II.2.4 (from II.2.5) Pathology, Tumor Board, and Consultation only Cases**
  - **II.2.5 (from II.2.6) Hematopoietic and Lymphoid Neoplasm**
  - **II.2.6 (from II.2.7) Benign/Borderline Brain and CNS Tumors**
  - **II.2.6.1 (from II.2.7.1) Date of Diagnosis for Benign/Borderline Brain and CNS Tumors**
  - **II.2.6.2 (from II.2.7.2) Malignant Transformation - Brain and CNS Tumors**
  - **II.2.6.3 (from II.2.7.2) Who Grade – Benign/Borderline Brain and CNS Tumors**

#### **II.2.7.4 CS Staging - Benign/Borderline Brain and CNS Tumors**

- ✓ This page was **deleted**. The CS items referenced are no longer required for cases diagnosed January 1, 2016 and forward.

#### **II.2.8 Borderline Ovarian Tumors**

- ✓ Updated page to reflect that Borderline Ovarian Tumors are no longer reportable to the CCR effective with cases diagnosed January 1, 2016 and forward.
- ✓ Added note to guide registrars to previous versions of Volume I for coding historical cases.

#### **III.2.7 Sex**

- ✓ **Code 3** - Updated code description to: Other, (intersex, disorders of sexual development/DDSD). The word hermaphrodite formerly classified under this code is an outdated term.

#### **III.2.17 Tobacco Use**

- ✓ Added instruction to explain that electronic cigarettes are not to be coded in this data item.

#### **III.3.5 Class of Case**

- ✓ **Class 34 and 35** - Added an end date of 12/31/2015 to the requirement of borderline ovarian tumors.

#### **IV.1 Text - Diagnostic Procedures Performed**

- ✓ Updated descriptions for the terms Tumor Size, Extension, and Lymph Nodes.
- ✓ Added description for the term Metastasis.

#### **IV.1.2 Text - X-Ray/Scans**

- ✓ Removed inappropriate coding guideline regarding Facility/Location of where the imaging was performed.
- ✓ To clarify what is collected in the Text-X-Ray section, instructions regarding the following items have been added to the Coding Guidelines section:
  - Collecting multiple procedures.
  - Multiple procedures performed on the same date.
  - Collection of the name of exam.
  - Added sub-bullets under “Extent to which the tumor has spread” to include spread within the organ, invasion to other tissues or adjacent organs and lymph nodes by direct extension.
  - Added bullet for distant disease or metastasis.
  - Added sub-bullet under “Distant disease or metastasis” to denote involvement of distant sites including distant lymph nodes.

#### **IV.1.6 Text – Pathology Findings**

- ✓ Revised first two bullets and sub bullets to include directions regarding how to record text information that supports the Path Report Identifier Data Items (1-5).

#### **IV.1.7 Text – Staging**

- ✓ Updated description to explain that this text field collects diagnostic information not already entered in other text fields.
- ✓ Added bullet to reinforce **not** to repeat information from other text fields.

### **V.3 ICD-O Morphology – Histology, Behavior, and Differentiation**

- ✓ Added note extending use of ICD-O-3 Histology Code Crosswalk through 2016.
- ✓ Updated Attachment A, extending the date through 2016.

#### **V.3.4 Behavior**

- ✓ Removed letter “b” under number 2 concerning requirement of borderline ovarian tumors.

### **V.4 Coding Systems - *REVISED Introduction page for the Coding Systems Pages***

- ✓ Separated Coding Systems from Staging Systems.

#### **V.4.1 Tumor Size - *NEW Introduction page for the Tumor Size Pages***

- ✓ Three new data items have been added in 2016 to collect information on tumor size of the solid, primary tumor at various points in the diagnosis and treatment of the reportable neoplasm. These data fields are: Tumor Size-Clinical, Tumor Size-Pathologic and Tumor Size-Summary. These data fields are independent from one another and have specific, unique coding instructions. Refer to each separate tumor size data item for the specific corresponding coding instructions.

##### **V.4.1.1 Tumor Size - Clinical - *NEW for 2016***

- ✓ Section added for this new data item. This data item records the size of a solid primary tumor before **any** treatment and is essential for treatment decision making and prognosis determination for many types of cancer.

##### **V.4.1.2 Tumor Size - *NEW for 2016***

- ✓ Section added for this new data item. This data item records the size of a solid primary tumor that has been resected. It is an important prognostic indicator and is valuable for both clinical practice and for research on surgically treated patients.

##### **V.4.1.3 Tumor Size - Summary - *NEW for 2016***

- ✓ Section added for this new data item. This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen. Tumor size is one indication of the extent of disease and is therefore used by clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts.

#### **V.4.2 Mets at Diagnosis – Bone, Brain, Distant LNs, Liver, Lung, and Other - *NEW for 2016***

- ✓ Section added for this new data item. These seven fields record the specific site of metastatic disease at diagnosis.

#### **V.4.3 (no number change) Lymph-Vascular Invasion**

- ✓ Removed fourth bullet referring registrars to the CS Manual.

#### **V.4.4 (from V.4.2) Collaborative Stage Data Collection System**

- ✓ Revised page to inform registrars of transition away from the Collaborative Stage Data Collection system.
- ✓ Listed Collaborative Stage items in which the California Cancer Registry will continue to require be collected.
- ✓ Added note to guide registrars to previous versions of Volume I for coding historical cases.

#### **V.4.4.1 (from V.4.2.1) CS Mets Bone, Brain, Liver, and Lung**

- ✓ With the new Mets Bone, Brain, Distant LN, Liver, Lung and Other data items added, a note has been added to this page to clarify these CS Mets fields will no longer be reportable with cases diagnosed January 1, 2016 and forward.
- ✓ Added note to guide registrars to previous versions of Volume I for coding historical cases.

#### **V.4.4.2 (from V.4.2.2) CS Site Specific Factors**

- ✓ Updated description of the CS Site Specific Factor Data Item.
- ✓ Revised instructions to include the continued requirement of CS Site Specific Factor data items for specific primary sites, applying to cases diagnosed January 1, 2016 and forward.
- ✓ Added note to guide registrars to previous versions of Volume I for coding historical cases.

#### **V.4.4.3 (from V.6) Tumor Markers**

- ✓ Moved this page from Staging Systems section to Coding Systems section.

#### **V.4.5 (from V.4.1) Extent of Disease**

- ✓ Renumbered page.

### **V.5 Staging Systems - *NEW Introduction page for the Staging Systems Pages***

- ✓ Separated Staging Systems from Coding Systems.

#### **V.5.1 (from V.5) Stage at Diagnosis**

- ✓ Revised table of requirements for 2016 CS Stage to state:
  - CS Stage no longer required, However, the following CS items will continue to be collected and are required by all facilities:
    - Required Site Specific Factors
    - Regional Nodes Positive
    - Regional Nodes Examined
    - Lymph-vascular invasion
- ✓ Minor formatting and typo fixes.

#### **V.5.2 (from V.5.1) Terms Indicating In Situ**

- ✓ Revised data item description.
- ✓ Removed DCIS and DIN duplication.
- ✓ Minor formatting changes.

#### **V.5.3 (from V.5.2) Ambiguous Terms for Extent of Disease**

- ✓ Added sub-headings for Summary Stage 2000 and AJCC TNM Stage.
- ✓ Added references to where information can be found regarding ambiguous terms for each of the staging systems.
- ✓ Removed bullet referring abstractor to Collaborative Stage Manual. This bullet refers to a page in CS which is no longer a requirement for 2016 forward.

#### **V.5.4 (from V.5.3) Staging Time Period**

- ✓ Renumbered page.

## **V.5.5 (from V.5.4) SEER Summary Stage**

- ✓ Moved requirement of directly coded SEER Summary Stage to the first Coding Instruction bullet rather than as a note.
- ✓ Revised first bullet under “Other SEER Summary Staging Considerations” to clarify information regarding outdated staging items: AJCC TNM (5<sup>th</sup> edition) and FIGO Stage (2000).

### **V.5.5.1 (from V.5.4.1) SEER - Summary Stage - Special Situations**

- ✓ Revised Code 8 Title, removing “SEER Summary Staging Not Applicable” as this code is to be used for Benign and Borderline Brain and/or CNS tumors only.
- ✓ Removed third bullet regarding the use of code 8 for other reportable benign tumors.

## **V.6 (from V.7) AJCC Staging**

- ✓ Revised data item description.
- ✓ Removed 2015 note regarding derived CS items as they are no longer required 2016 forward.
- ✓ Added first bullet in Coding Guidelines stating “TNM Stage is to be directly coded for date of diagnoses January 1, 2016 and forward.”
- ✓ Moved information from third bullet in Coding Guidelines into new section for TNM Indicators/Prefixes
- ✓ Added a section for TNM Indicators/Prefixes to describe the use of the “c” and “p” values.
  - Implementation and use is effective in 2016, regardless of date of diagnosis for coding of TNM Indicators/Prefixes
- ✓ Separated “Stage Group”, “Timing Rules for TNM Stage”, and “TNM Classification” from this page and introduced them into pages within this section. The pages within section V.7 may have been added, revised, or renumbered.

### **V.6.1 (from V.7.1) TNM Staging Classifications**

- ✓ Revised description of data item to indicate that the Stage Classifications indicate the point in time and the basis/source of the information used to stage the case.
- ✓ Moved this information from the AJCC TNM Staging page and created its own page to clarify the use of the letter prefix c, p, and y.

### **V.6.2 Clinical Staging - *NEW Introduction Page for the Clinical Staging Pages.***

- ✓ This page provides information regarding criteria and timing rules for Clinical Staging.

#### **V.6.2.1 Clinical T - *NEW Page for 2016***

- ✓ Section added for this new data item. This field evaluates the primary tumor (T) and reflects tumor size/extension of the tumor known prior to the start of any therapy.

#### **V.6.2.2 Clinical N - *NEW Page for 2016***

- ✓ Section added for this new data item. This field identifies the presence or absence of regional lymph node (N) involvement and describes the extent of regional node involvement known prior to the start of any therapy.

#### **V.6.2.3 Clinical M - *NEW Page for 2016***

- ✓ Section added for this new data item. This field identifies the presence or absence of distant metastasis (M) of the tumor known prior to the start or any therapy.

#### V.6.2.4 Clinical Stage Group - *NEW Page for 2016*

- ✓ Section added for this new data item. This field identifies the extent of disease based on the combination of T, N, and M data items known prior to the start of any therapy.

#### V.6.2.5 Clinical Stage Descriptor - Prefix/Suffix - *NEW Page for 2016*

- ✓ Section added for this new data item. This field isolates the clinical stage (prefix/suffix) descriptor of the tumor prior to the start of any therapy. The stage descriptor identifies special cases that need separate analysis. These descriptors supplement but do not change the stage group.

#### V.6.2.6 (from V.7.2) TNM Staged By - Clinical Stage

- ✓ Page renamed to TNM Staged By - Clinical Stage from TNM Coder (Clinical Stage, Pathological, and Other).
- ✓ Separated TNM Staged By - Clinical from Staged By - Pathologic.
- ✓ Added Coding Instructions Section.
- ✓ **This data item has been expanded to two digits to accommodate new codes.**

##### Codes:

NEW Code	NEW Description
00	Not staged
10	Physician, NOS, or physician type not specified in codes 11-15
11	Surgeon
12	Radiation Oncologist
13	Medical Oncologist
14	Pathologist
15	Multiple Physicians; tumor board; etc.
20	Cancer registrar
30	Cancer registrar and physician
40	Nurse, physician assistant, or other non-physician medical staff
50	Staging assigned at another facility
60	Staging by Central Registry
88	Case not eligible for staging
90	Staged but unknown who assigned stage

#### V.6.3 Pathologic Staging - *NEW Introduction Page for the Pathologic Staging Pages.*

- ✓ This page provides information regarding criteria and timing rules for Pathologic Staging.

#### V.6.3.1 Pathologic T - *NEW Page for 2016*

- ✓ Section added for this new data item. This field evaluates the primary tumor (T) and reflects tumor size/extension of the tumor known following the completion of therapy.

#### V.6.3.2 Pathologic N - *NEW Page for 2016*

- ✓ Section added for this new data item. This field identifies the presence or absence of regional lymph node (N) involvement and describes the extent of regional node involvement known following the completion of surgical therapy.



#### **V.6.3.3 Pathologic M - *NEW Page for 2016***

- ✓ Section added for this new data item. This field identifies the presence or absence of distant metastasis (M) of the tumor known following the completion of surgical therapy.

#### **V.6.3.4 Pathologic Stage Group - *NEW Page for 2016***

- ✓ Section added for this new data item. This field identifies the extent of disease based on the combination of T, N, and M data items known following the completion of surgical therapy.

#### **V.6.3.5 Pathologic Stage Descriptor - Prefix/Suffix - *NEW Page for 2016***

- ✓ Section added for this new data item. This field isolates the pathologic stage (prefix/suffix) descriptor known following the completion of surgical therapy. The stage descriptor identifies special cases that need separate analysis. These descriptors supplement but do not change the stage group.

#### **V.6.3.6 TNM Staged By - Pathologic - *NEW Page for 2016***

- ✓ Separated TNM Staged By - Pathologic from TNM Staged By - Clinical.
- ✓ Named page: TNM Staged By - Pathologic Stage for consistency in naming.
- ✓ Added Coding Instructions section.
- ✓ **This data item has been expanded to two digits to accommodate new codes.**

##### **Codes:**

<b>NEW Code</b>	<b>NEW Description</b>
00	Not staged
10	Physician, NOS, or physician type not specified in codes 11-15
11	Surgeon
12	Radiation Oncologist
13	Medical Oncologist
14	Pathologist
15	Multiple Physicians; tumor board; etc.
20	Cancer registrar
30	Cancer registrar and physician
40	Nurse, physician assistant, or other non-physician medical staff
50	Staging assigned at another facility
60	Staging by Central Registry
88	Case not eligible for staging
90	Staged but unknown who assigned stage

#### **V.6.4 (from V.7.3) AJCC TNM Edition Number**

- ✓ Added “AJCC” to the title of the page.
- ✓ Renumbered page.
- ✓ Fixed typo.

#### **V.7 (from V.7.4) Pediatric Stage**

- ✓ Renumbered page.



### **V.7.1 (from V.7.4.1) Pediatric Stage Group**

- ✓ Renumbered page.

### **V.7.2 (from V.7.4.2) Pediatric Protocols**

- ✓ Renumbered page.

### **V.7.3 (from V.7.4.3) Staged By - Pediatric Stage**

- ✓ Added “Staged By” to the page title to be consistent with the TNM Staged By pages.
- ✓ Fixed typo.

## **VI.1 First Course of Treatment - Definitions and Guidelines**

- ✓ Minor formatting and typo fixes.

### **VI.1.1 First Course of Treatment - Special Situations**

- ✓ Minor formatting and typo fixes.

### **VI.1.2 First Course of Treatment - Data Entry**

- ✓ Updated first bullet under “Coding Instructions” to refer registrars to the most current Hematopoietic and Lymphoid Database and Hematopoietic & Lymphoid Neoplasm for coding instructions on entering first course of therapy for hematopoietic and lymphoid neoplasms.

### **VI.2.3 Regional Lymph Nodes Examined**

- ✓ Added NOTE: Effective with cases diagnosed January 1, 2016 and forward, the AJCC definition takes precedence if the definition of regional nodes differs between the AJCC Cancer Staging. Manual and the SEER Program Coding and Staging Manual.
- ✓ Removed second and third bullet referring to Collaborative Stage data items that are no longer collected.
- ✓ Minor formatting and typo fixes.

#### **VI.2.3.1 Regional Lymph Nodes Positive**

- ✓ Added NOTE: Effective with cases diagnosed January 1, 2016 and forward, the AJCC definition takes precedence if the definition of regional nodes differs between the AJCC Cancer Staging Manual and the SEER Program Coding and Staging Manual.
- ✓ Removed portion of second bullet that refers to Collaborative Stage data items no longer collected.
- ✓ Minor formatting and typo fixes.

### **VI.2.7 Surgical Margins of the Primary Site**

- ✓ Revised data item description.
- ✓ This data item is required to be collected for cases diagnosed January 1, 2016 and forward.
- ✓ Added “Coding Instructions.”
- ✓ Added Codes table.

### **VI.2.13 Systemic Therapy with Surgery Sequence**

- ✓ Removed effective date from the data item description.
- ✓ Added effective date to “Coding Instructions” section.
- ✓ Minor formatting and typo fixes.

### **VI.3.5 Date of Radiation Therapy**

- ✓ Added Coding Instructions.

### **VI.4.3 Date of Chemotherapy**

- ✓ Added Coding Instructions.

### **VI.5.3 Date of Hormone Therapy**

- ✓ Added Coding Instructions.

### **VI.6.2 Date of Immunotherapy**

- ✓ Added Coding Instructions.

### **VI.7.1 Date of Transplant/Endocrine Procedure**

- ✓ Added Coding Instructions.

### **VI.8.2 Date of Other Therapy**

- ✓ Added Coding Instructions.

## **VII.1 Follow-Up Information**

- ✓ Added first bullet concerning the use of the Modified Record to transmit data modifications for abstracts already submitted as New Case Records.
- ✓ Provided a link to the Modified Record page.
- ✓ Minor formatting and typo fixes.

### **VII.2.1 Date of Last Contact (AKA – Date Last Pt FU)**

- ✓ Revised data item description.
- ✓ Added first bullet to clarify that this date is the most current date the patient was seen, heard from, or their date of death.

### **VII.2.3 Date of Last Tumor Status (AKA – Date Last Cancer Status)**

- ✓ Revised data item description.
- ✓ Updated Coding Instructions to clarify that this data item collects the date of last contact with the patient where there is specific information about the tumor being reported by tumor status.
- ✓ Added clarification bullet to indicate that this date can be different depending on follow-up for each tumor when there are multiple tumors.

### **VII.2.4 Tumor Status**

- ✓ Revised data item description.
- ✓ Added Coding Instruction to confirm that the value may be different for each primary.

## **VIII.1 Text - Remarks**

- ✓ Renamed from Remarks and Final Diagnosis
- ✓ Separated Text - Remarks from Text - Final Diagnosis because these are two separate text fields.

## **VIII.2 Text - Final Diagnosis - *NEW Page for 2016***

- ✓ Separated Text - Final Diagnosis from Text - Remarks because these are two separate text fields.

### **VIII.3 (from VIII.2) Regional Data**

- ✓ Renumbered page.

### **VIII.4 (from VIII.3) Extra Facility Information**

- ✓ Renumbered page.
- ✓ Minor formatting and typo fixes.

### **IX.1.2 Modified Record (from Corrections)**

- ✓ Entire page updated to convey that the CCR now requires facilities to use the Modified Record instead of the former Update/Correction and Follow-Up Records to transmit data modifications for abstracts already submitted as New Case Records.

### **Terms and Definitions**

- ✓ Added Tumor Markers definition to this page because the page previously dedicated to “Tumor Markers” has been deleted. The information in the deleted page only included a definition and a link to the Collaborative Staging Website.
- ✓ Repurposed page V.6 to the new AJCC pages.

## **CHANGES to APPENDICES**

### **Appendix F: California Reporting Facility Codes**

- ✓ Updated with current California Reporting Facility Code Numbers.

### **Appendix J**

- ✓ Removed “as well as borderline ovarian cancer” as part of the statement for required borderline tumors.

### **Appendix Q-2: FORDS Surgery Codes**

- ✓ Revised all site pages with exclusion update:
  - (Except for M-9727, 9732, 9741-9742, 9762-9809, 9832, 9840-9931, 9945-9946, 9950-9967, 9975-9992)
- ✓ SKIN:
  - Added the following clarification note for codes 45-47 - If the excision or re-excision has microscopically confirmed negative margins **OR** the margins are more than 1cm but are not microscopically confirmed, use the appropriate code, 20-36.

### **Appendix U: Data Items and their Required Status**

- ✓ Requirements updated for 2016 forward.

○ Lymph-Vascular Invasion	○ Surgical Margins Summary
○ Mets at DX-Bone	○ TNM Descriptor (Clinical)
○ Mets at DX-Brain	○ TNM Descriptor (Path)
○ Mets at DX-Distant LN	○ TNM Edition
○ Mets at DX-Liver	○ TNM M Code (Clinical)
○ Mets at DX-Lung	○ TNM M Code (Path)
○ Mets at DX-Other	○ TNM N Code (Clinical)

- TNM N Code (Path)
- TNM Stage Group (Clinical)
- TNM Stage Group (Path)
- TNM Staged By (Clinical)
- TNM Staged By (Path)
- TNM T Code (Clinical)
- TNM T Code (Path)

- ✓ Updated requirements to coincide with the California Cancer Reporting Standards, Volume II.

#### **Appendix Y: Index to CS Site Specific Factors**

- ✓ Updated page to specify that the CSv02.05 - Interactive Appendix was updated in 2016.
- ✓ SEER is **no longer** requiring the following Site Specific Factors. As a result, each Site and Site Specific Factor listed below has been updated in the interactive pages to remove the requirement from CCR/SEER:
  - Appendix - SSF 2
  - Bile Ducts Intra Hepatic - SSF 10
  - Carcinoid Appendix - SSF 2
  - Colon - SSF 2
  - Esophagus - SSF 1
  - Esophagus GE Junction - SSF 1
  - Lacrimal Gland - SSF 3
  - Melanoma Skin - SSF 3
  - Merkel Cell Penis - SSF 3
  - Merkel Cell Scrotum - SSF 3
  - Merkel Cell Vulva - SSF 3
  - NET Colon - SSF 2
  - NET Rectum - SSF 2
  - NET Stomach - SSF 3
  - Peritoneum - SSF 25
  - Peritoneum Female Gen - SSF 25
  - Prostate - SSF 3
  - Rectum - SSF 2
  - Retinoblastoma - SSF 1
  - Skin Eyelid - SSF 3
  - Small Intestine - SSF 2
  - Stomach - SSF 1
- ✓ Breast Page: Removed X (requirement) in the CoC column for requirement as this was incorrectly marked a previous release.
- ✓ GIST Peritoneum: Removed X (requirement) in the CCR/SEER Column for SSF 25 as this was incorrectly marked and was correctly collected in SSF 10.
- ✓ Soft Palate: Removed X (requirement) in the CCR/SEER Column for SSF 25 as this was incorrectly marked and was correctly collected in SSF 10.